Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura

British Journal of Haematology

Volumn 164, Issue 6, 2014, Pages 900-902

  Mazepa, Marshall A ^a   Raval, Jay S ^a   Moll, Stephan ^a   Ma, Alice ^a   Park, Yara A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Thrombotic haemolytic anaemias; Thrombotic thrombocytopenic purpura

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE WITH A THROMBOSPONDIN TYPE 1 MOTIF MEMBER 13 INHIBITOR; AUTOANTIBODY; BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANTIBODY TITER; B LYMPHOCYTE; CASE REPORT; DISEASE EXACERBATION; FEMALE; HEMOGLOBINURIA; HEMOLYSIS; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; RETREATMENT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BORTEZOMIB; THROMBOTIC HAEMOLYTIC ANAEMIAS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; BORONIC ACIDS; FEMALE; HUMANS; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; PYRAZINES; RECURRENCE; REMISSION INDUCTION;

EID: 84896697168     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12696     Document Type: Letter

References (8)

1. Chapin, J., Weksler, B., Magro, C. & Laurence, J. (2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 157, 772-774.
2. Everly, M.J., Everly, J.J., Susskind, B., Brailey, P., Arend, L.J., Alloway, R.R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A.H., Cardi, M., Wadih, G., Brown, E., Tevar, A. & Woodle, E.S. (2009) Proteasome inhibition reduces donor-specific antibody levels. Transplantation Proceedings, 41, 105-107.
3. Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lammle, B. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine, 339, 1578-1584.
4. George, J.N. (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood, 116, 4060-4069.
5. Ginzler, E.M., Dooley, M.A., Aranow, C., Kim, M.Y., Buyon, J., Merrill, J.T., Petri, M., Gilkeson, G.S., Wallace, D.J., Weisman, M.H. & Appel, G.B. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New England Journal of Medicine, 353, 2219-2228.
6. Scully, M., McDonald, V., Cavenagh, J., Hunt, B.J., Longair, I., Cohen, H. & Machin, S.J. (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood, 118, 1746-1753.
7. Shortt, J., Oh, D.H. & Opat, S.S. (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. New England Journal of Medicine, 368, 90-92.
8. Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 1585-1594.